Chiome Bioscience (TSE:4583) Operating Margin %: -78.05% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4583 Chiome Bioscience Inc TSE:4583
38 GF Score
Price 円69.00
GF Value 円106.02
Valuation Possible Value Trap
! 1 Warning Sign
View Full Analysis

What is Chiome Bioscience Operating Margin %?

Chiome Bioscience TSE:4583 -1.43% 38 Operating Margin % is -78.05% as of Dec. 2025. GuruFocus rates TSE:4583 with a GF Score™ of 38/100 and a GF Value™ of 円106.02 (Possible Value Trap). The stock has 1 warning sign investors should review. Among 940 Biotechnology companies, Chiome Bioscience ranks worse than 55.32% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Chiome Bioscience's Operating Income for the three months ended in Dec. 2025 was 円-174.4 Mil. Chiome Bioscience's Revenue for the three months ended in Dec. 2025 was 円223.5 Mil. Therefore, Chiome Bioscience's Operating Margin % for the quarter that ended in Dec. 2025 was -78.05%.

Good Sign:

Chiome Bioscience Inc operating margin is expanding. Margin expansion is usually a good sign.

The historical rank and industry rank for Chiome Bioscience's Operating Margin % or its related term are showing as below:

TSE:4583' s Operating Margin % Range Over the Past 10 Years
Min: -723.1   Med: -201.32   Max: -132.03
Current: -140.37


TSE:4583's Operating Margin % is ranked worse than
55.32% of 940 companies
in the Biotechnology industry
Industry Median: -86.55 vs TSE:4583: -140.37

Chiome Bioscience's 5-Year Average Operating Margin % Growth Rate was 9.70% per year.

Chiome Bioscience's Operating Income for the three months ended in Dec. 2025 was 円-174.4 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 was 円-679.0 Mil.


Chiome Bioscience  (TSE:4583) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Chiome Bioscience Operating Margin % Related Terms


Chiome Bioscience Operating Margin % Historical Data

* Premium members only.

The historical data trend for Chiome Bioscience's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chiome Bioscience Operating Margin % Chart

Chiome Bioscience Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -187.16 -199.53 -176.59 -132.03 -165.14

Chiome Bioscience Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -190.74 -240.73 0.00 -78.05 -157.88

TSE:4583 vs VRTX, REGN, ALNY: Operating Margin % Comparison

For the Biotechnology subindustry, Chiome Bioscience's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chiome Bioscience Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chiome Bioscience's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Chiome Bioscience's Operating Margin % falls into.


TSE:4583
38GF Score
Chiome Bioscience Inc TSE:4583
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chiome Bioscience Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Chiome Bioscience's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=-979.774 / 593.29
=-165.14 %

Chiome Bioscience's Operating Margin % for the quarter that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2025 ) / Revenue (Q: Dec. 2025 )
=-174.427 / 223.475
=-78.05 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of -78.05% mean?
Chiome Bioscience (TSE:4583) has a Operating Margin % of -78.05% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on Chiome Bioscience and its competitors. According to the industry distribution chart, Chiome Bioscience ranks #520 out of 940 companies in the Biotechnology industry, placing it in the top 55.3%.
Is Chiome Bioscience's Operating Margin % too high?
Chiome Bioscience's current Operating Margin % is -78.05%. Based on the distribution chart, Chiome Bioscience ranks #520 out of 940 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Chiome Bioscience has a GF Score™ of 38/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Chiome Bioscience's Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chiome Bioscience ranks #520 out of 940 companies for Operating Margin %. This places Chiome Bioscience in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Chiome Bioscience and its competitors. Chiome Bioscience's current Operating Margin % is -78.05%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chiome Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Chiome Bioscience (TSE:4583) is currently considered Possible Value Trap. The stock's GF Value™ is 円106.02, compared to a current price of 円69.00 — trading 34.9% below its estimated fair value. The current Operating Margin % is -78.05%. Chiome Bioscience's overall GF Score™ is 38/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Chiome Bioscience (TSE:4583), the current Operating Margin % is -78.05% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chiome Bioscience (TSE:4583) Overvalued in 2026?

Based on GuruFocus' analysis, Chiome Bioscience stock appears to be undervalued. The current stock price of 円69.00 is trading 34.9% below its estimated GF Value™ of 円106.02. GuruFocus considers Chiome Bioscience to be Possible Value Trap.

Key valuation signals for TSE:4583:

  • Operating Margin %: -78.05%
  • GF Value™: 円106.02 vs. price of 円69.00 (34.9% below fair value)
  • GF Score™: 38/100 with 1 warning sign

No single metric tells the full story. See the TSE:4583 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Chiome Bioscience Business Description

Address 3-12-1 Honmachi, No. 6, Sumitomo Fudosan Nishi Shinjuku Building, Shibuya-ku, Tokyo, JPN, 151-0071
Chiome Bioscience Inc is engaged in the discovery and development of antibody drugs, focusing on early-stage research and initial clinical trials. The company operates through two reportable segments: the Drug Discovery segment and the Drug Discovery Support segment. The Drug Discovery segment conducts research on antibody creation for diseases with high unmet medical needs and aims to generate revenue through licensing agreements, upfront payments, milestone payments, and royalties. The Drug Discovery Support segment provides services such as antibody production and related support using proprietary antibody technologies, catering to pharmaceutical and diagnostic companies as well as academic institutions.
38GF Score

Get the complete analysis for TSE:4583

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円69.00
Price
円106.02
GF Value